Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician?s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PDL1 Agents in the Early Setting Whose Tumors do Express PD-L1
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC NeoTRACT
Understanding and Predicting Breast Cancer Events after Treatment UPBEAT
A Phase II Trial of Sacituzumab Govitecan IMMU-132 NSC 820016 for Patients with HER2-Negative Breast Cancer and Brain Metastases
Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
Study Type: Supportive Care
Phase: III
NCTID: NCT05896189
Principal Investigator:
Jamie Myers